A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NSCLC / non-SCLC

[Related PubMed/MEDLINE]
Total Number of Papers: 55
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NSCLC  (>> Co-occurring Abbreviation)
Long Form:   non-SCLC
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Bavachinin Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Small Cell Lung Cancer and Shows an Antitumor Effect in the Xenograft Model. SCLC
2021 Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer. SCLC
2021 Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study. EGFR, mPFS, SCLC, TKI
2021 MRI Texture Analysis for the Prediction of Stereotactic Radiosurgery Outcomes in Brain Metastases from Lung Cancer. C-index, MRI, OS, PFS, RLN, SCLC, SRS
2020 Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? ICPIs, SCLC, TKIs
2020 The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. HUS, SCLC
2019 Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. LCNEC, SCLC
2019 Downregulation of miR-3934-5p enhances A549 cell sensitivity to cisplatin by targeting TP53INP1. Bcl-2, miR, SCLC, si, TP53INP1
2019 Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study. LCNEC, SCLC, SEER
10  2019 Spectral histopathology of the lung: A review of two large studies. SCLC, SHP
11  2019 Strategies to prevent brain metastasis. OS, PCI, SCLC, WBRT
12  2018 Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone. GHRH, SCLC
13  2018 Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report. ALK, SCLC
14  2018 The 180 splice variant of NCAM-containing exon 18-is specifically expressed in small cell lung cancer cells. CTL, NCAM, PBMC, SCLC
15  2017 Nidogen-1 Degraded by Cathepsin S can be Quantified in Serum and is Associated with Non-Small Cell Lung Cancer. BM, CatS, SCLC
16  2016 Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma. SCLC
17  2016 Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer. CFH, PCR-RFLP, SCLC
18  2016 Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors. SCLC, WES
19  2016 Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. LCNEC, MSK-IMPACT, SCLC
20  2016 SRSF5: a novel marker for small-cell lung cancer and pleural metastatic cancer. LC, PE, SCLC, SRSFs
21  2015 Lower serum levels of bilirubin in the newly diagnosed lung cancer patients: A case-control study in China. SCLC
22  2014 Class III/IV POU transcription factors expressed in small cell lung cancer cells are involved in proneural/neuroendocrine differentiation. SCLC
23  2014 Diffusion-weighted imaging vs STIR turbo SE imaging: capability for quantitative differentiation of small-cell lung cancer from non-small-cell lung cancer. ADC, CRs, DWI, SCLC, STIR
24  2013 POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer. ASCL1, CHGA, NCAM1, ND1, SCLC, SYP
25  2013 Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009. SCLC
26  2011 Animal models of lung cancer characterization and use for chemoprevention research. SCLC
27  2011 C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin. NQO1, SCLC
28  2011 Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: a systematic review. AUC, CNKI, ProGRP31-98, SCLC, SDTMG, SROC
29  2011 Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. GWAS, LCL, OS, SCLC, SNP
30  2010 HRQoL changes, mood disorders and satisfaction after treatment in an unselected population of patients with lung cancer. HRQoL, SCLC
31  2009 CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours. GIST, SCLC
32  2009 Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. IGFBP, SCLC
33  2007 Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. BN, GRP, LRP, SCLC
34  2007 Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). EBUS, FB, SCLC, TTNA
35  2006 Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. SCLC
36  2005 Oxytocin receptor pattern of expression in primary lung cancer and in normal human lung. SCLC
37  2003 Gamma knife radiosurgery for metastatic brain tumors from lung cancer: a comparison between small cell and non-small cell carcinoma. GKS, SCLC
38  2002 AH6809 antagonizes non-small cell lung cancer prostaglandin receptors. PG, SCLC
39  2002 Differential inactivation of caspase-8 in lung cancers. CASP8, SCLC
40  2002 Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. CASP8, DISC, SCLC
41  2002 Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features. NE, SCLC
42  2002 Upstream stimulatory factor activates the vasopressin promoter via multiple motifs, including a non-canonical E-box. AVP, SCLC, USF
43  2001 9-Nitrocamptothecin is an effective drug for the treatment of human lung tumors: comparison of in vitro and in vivo studies. 9NC, SCLC
44  2001 Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. PGE2, SCLC, SST, VEGF, VIP
45  1998 Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Abs, SCLC
46  1997 Dose-intensive therapy in lung cancer. ED, IL, MRT, SCLC
47  1997 The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. SCLC, TBB
48  1997 [International consensus for lung cancer treatment]. SCLC
49  1996 ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells. ELISA, ICAM-1, IFN-gamma, LAK, NCI, SCLC, sICAM-1, TNF-alpha
50  1996 Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). GHRH, SCLC
51  1991 Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. GRP, NMB, SCLC
52  1990 Overlap of nuclear diameters in lung cancer cells. NDs, SCLC
53  1988 Immunohistochemical evaluation of a panel of monoclonal antibodies for the diagnosis of small cell lung cancer. mAbs, SCLC
54  1988 Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. NE, NSE, SCLC
55  1986 Paucity of beta 2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors. beta2m, SCLC